Main Page
Faculty Deanship
Dean
Health Empowerment Unit
Strategic Planning Unit
Development and Quality Unit
Medical and Bioethics Unit
Vice Dean for Graduate Studies and Research
Vice Dean for Female Section
Vice dean for Academic Affairs
Examination and Assessment Unit
Internship and Alumni Unit
Student Research Unit
E-learning Unit
Student Mentoring and Support Unit
Community Service Unit
Talent and Creativity Care Unit
Continuing Education Unit
Neuroscience Research Unit
Vice Deanship of Clinical Affairs / Administration
Organizational Structure
Departments
Basic Sciences
Department of Anatomy
Department of Pharmacology
Department of Pathology
Department of Microbiology and Medical Parasitolog
Deparment of Clinical Biochemistry
Department of Physiology
Department of Medical Genetics
Clinical Sciences
Department of Otorhinolaryngology
Department of Obstetrics and Gynecology
Department of Hematology
Department of Medical Education
Department of Anesthesia
Department of Family Medicine
Department of Community Medicine
Department of Surgery
Department of Orthopedic Surgery
Department of ophthalmology
Department of Radiology
Department of Internal Medicine
Department of Pediatrics
Department of Emergency Medicine
Department of Urology
Department of Dermatology
Latest News
عربي
English
About
Admission
Academic
Research and Innovations
University Life
E-Services
Search
Faculty of Medicine
Document Details
Document Type
:
Article In Journal
Document Title
:
Potentially serious Lamotrigine-related skin rash
Potentially serious Lamotrigine-related skin rash
Subject
:
Pediatric Neurology
Document Language
:
English
Abstract
:
Objective: To report our experience with lamotrigine (LTG)-related skin rash in children with epilepsy. Methods: We identified a series of consecutive children with epilepsy treated with LTG prospectively over a 5- year period ending 1st October 2005 at King Abdul-Aziz University Hospital and King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia. Results: Of 207 children on LTG, 15 (7.2%) developed a skin rash with ages ranging between 3-12 years (mean 7.5). We used LTG as monotherapy in 3/15 and as add on in 12/15, mostly (10/15) in addition to valproic acid (VPA). The rash was mild with complete recovery in 7 children (47%). The remaining 8 (3.9% of the total) had severe rash that necessitated admission to hospital. Seven out of these 8 children were also receiving VPA. One child had superimposed secondary bacterial infection and admitted for intravenous antibiotics. Two children recovered slowly with extensive postinflammatory hyperpigmentation. We diagnosed Stevens-Johnson syndrome in 5 children (2.4% of the total). One of these 5 children had progressive symptoms that evolved to toxic epidermal necrolysis. He required prolonged intensive care admission and developed sepsis with disseminated intravascular coagulopathy. He deteriorated despite supportive therapy, and died 5 weeks after the initiation of LTG therapy. Conclusions: Lamotrigine is a novel antiepileptic drug with a favorable therapeutic profile and good tolerability. However, LTG-related skin rash is a potentially serious adverse event that should be carefully monitored. Although the risk is small, one should weigh this against the potential benefits, particularly in children on VPA
ISSN
:
1319-6138
Journal Name
:
Neurosciences
Volume
:
12
Issue Number
:
1
Publishing Year
:
1428 AH
2007 AD
Article Type
:
Article
Added Date
:
Saturday, May 17, 2008
Researchers
Researcher Name (Arabic)
Researcher Name (English)
Researcher Type
Dr Grade
Email
محمد جان
Jan, Mohammed
Researcher
Doctorate
Files
File Name
Type
Description
Lamotrigine_Rash.pdf
pdf
مشاهدة المقالة العلمية كاملة
Back To Researches Page